Full text is available at the source.
Personalized mRNA Vaccine May Produce Lasting Immune Protection in Triple-Negative Breast Cancer
Updated
Abstract
Essence
A personalized mRNA neoantigen vaccine produced durable multitarget T-cell responses in early-stage triple-negative breast cancer.
Evidence
A small adjuvant trial in patients with early-stage TNBC tested the vaccine alone and followed vaccine-induced T-cell responses over years.
Caveat
The abstract reports immune-response findings in a small trial, not evidence that the vaccine improves recurrence or survival.
Simplified
mRNA Technology